On this page
Update, October 28, 2026
HHS filed a draft interim enforcement-discretion policy on October 28, 2026. It is on Federal Register public inspection as document 2026-22192, and it is scheduled to publish on October 30. Comments stay open for two weeks after that publication date. Appendix A names six peptides: BPC-157, TB-500, MOTS-c, KPV, Epitalon, and Semax.
HHS says it does not intend to take action against a state-licensed pharmacy, a federal facility, or a licensed physician who compounds one of those peptides when the conditions are met, including a prescription for a specific patient. FDA has not approved any of the six. The 503A Bulks List is unchanged. The Secretary wrote that the policy is meant to discourage research-use-only peptides supplied by foreign manufacturers. NBC News reported the filing the same day.
The conditions, the salt forms, and the routes are on is BPC-157 legal?. What the policy means for a research-use-only label is on research use only peptides. The two compound profiles that exist for this list are BPC-157 and MOTS-c. KPV, Epitalon, and Semax do not have profiles here. TB-500 is covered with BPC-157 on BPC-157 vs TB-500.
Read the beginner page before the brand names
What are peptides? is the page that answers the chemistry question: a short chain of amino acids, and the line FDA uses when a chain is long enough to count as a protein. It also separates three things people mash together: an approved medicine, a drug still in a trial, and a vial sold as "research use only."
That page is the one to send someone who asked what the word means. This page is the one to send someone who already has a product name and wants the file. Publishing a second "what are peptides" URL would only split the same search. We did not.
If a sentence on a forum uses "randomized," "hazard ratio," or "estimand," the glossary is the definition, and methods is how this site decides a human trial outranks a mouse paper. The evidence ranking puts the published profiles in that order. Semaglutide is at the top because the human trials are large. BPC-157 is not, because they are not.
Approved GLP-1 medicines have their own list
Ozempic, Wegovy, Mounjaro, Zepbound, and Foundayo are the five names on the GLP-1 drugs list. Two of them are semaglutide. Two are tirzepatide. Foundayo is orforglipron, and the US label describes a small molecule, not a peptide. The list gives the US approval and the Canadian record we could verify. It does not give a price, and it does not say which one a person should take.
Read this next What are peptides?
Ozempic vs Wegovy stays on those two pens: same molecule, different labels, different weekly strengths on the labels. Mounjaro vs Zepbound is the same kind of file for tirzepatide. The Wegovy pill is the tablet on its own. Foundayo vs the Wegovy pill is the tablet comparison, including the empty-stomach rule on the Wegovy tablet label. Generic semaglutide in Canada is the notice-of-compliance file, separate from the US brands. The head-to-head weight trial of the two peptides is semaglutide vs tirzepatide.
Older GLP-1 drugs, and Rybelsus, are real products and are outside that five-name list. The semaglutide research profile is where those semaglutide products are separated. The topic page that collects the weight trials is weight management.
Food and supplies sit on their own pages. The best protein powder for GLP-1 users covers a protein shake when meals get small. Protein bars, multivitamins, and vitamins and hair loss use brand labels and the trial rates already in print. None of them is a dose calculator. Used pens go to sharps containers for Zepbound, Mounjaro and Wegovy. Skin serums are copper peptides vs retinol and copper peptides for hair.
Safety questions are not the same as trial questions
A compounded copy of an approved drug, a telehealth ad that says "same as Mounjaro," and a research-use-only vial of BPC-157 are three different legal files. They share a shopping problem, which is why they sit together on safety and buying.
Compounded semaglutide vs Ozempic is the semaglutide version. Compounded tirzepatide is the shortage calendar for Mounjaro and Zepbound copies. Research use only peptides is the explainer for the seller's line, including the August 24, 2026 letters. Is BPC-157 legal? is the US compounding record, including the October 28, 2026 HHS draft, and the Health Canada advisory. The sport rules are a different page, is BPC-157 banned for athletes, because a WADA line and an FDA bulks list are not the same document.
Tissue-repair claims, mostly animal studies, are on tissue repair. The human pilots are listed on BPC-157 human trials.
Unapproved names stay off the GLP-1 list
Retatrutide is the one people ask about next, and it is not approved. The retatrutide FDA approval article has Lilly's filing plan and the classification fight. The TRIUMPH results are the published weight numbers. The other late-stage names we could tie to a registry record or a sponsor filing are on coming soon.
That tracker leaves mazdutide off. A regulator or sponsor page for it was not opened for this edition, and a blog's percentage is not a substitute. It also leaves Foundayo and the Wegovy tablet off, because those are already approved and already on the GLP-1 list.
A product sold online under a trial name is not the drug in the trial. The pipeline page says that in the row, and the retatrutide article says it with the reports Lilly and FDA have already described.
What you will not find from this map
No seller, no coupon, and no dose schedule. Doses show up on the drug pages only when a label or a trial used that strength, and they are labeled as such. Country status is United States, Canada, and a short note when another regulator was checked. Dollars are not converted into Canadian dollars, or the other way around.
If a page is wrong, the correction path is corrections. Send the source. The study library holds the individual study summaries that the profiles cite.
Common questions
Is this the same page as "what are peptides"?
No. What are peptides? explains the chemistry and the three kinds of product. This page is the map.
Where is the GLP-1 drugs list?
On the GLP-1 drugs list: Ozempic, Wegovy, Mounjaro, Zepbound, and Foundayo, with the US and Canadian record for each name.
Where do I check a compounded drug or a research vial?
Safety and buying links the compounded semaglutide and tirzepatide pages, the March 2026 telehealth letters, and is BPC-157 legal.
Which drugs are still in trials?
Coming soon lists the rows this site could verify. Foundayo and the Wegovy tablet are already approved, so they stay on the GLP-1 list.
